“I’d like to think of regulatory reform in terms of painting a house … Typically, repainting needs to occur every few years, and before you do it, you need to strip the layers of paint underneath” — Seema Verma, administrator for the Centers for Medicare and Medicaid Services, announcing the agency’s “Patients Over Paperwork” initiative.
“That’s the complication that has led to decreased enthusiasm here in the U.S. The surgeons have to decide to do this.” — Norah Terrault, MD, of the University of California San Francisco, on the feasibility of so-called split liver transplants.
“Sex is such an important risk modifier that it’s included in heart risk calculators … [but we find] that it doesn’t hold true in people with NAFLD; women are not protected more than men.” – Alina Allen, MD, of the Mayo Clinic in Rochester, Minnesota on a study of non-alcoholic fatty liver disease and cardiovascular risk.
“I am impressed by the uptake and growth of ‘Choosing Wisely’ in just 5 years. It has allowed us to tap into our professionalism and say, ‘This is really important.’ But there is still much work to do.” – Eve Kerr, MD, professor of internal medicine at the University of Michigan in Ann Arbor, on the “Choosing Wisely” initiative.
“I, too in my practice, am seeing 20-year-olds presenting with cirrhosis.” – Norah Turreault, MD, of the University of California San Francisco, on the condition’s prevalence across the population.
“We’ve always done chronics.” — Russell Wiesner, MD, of the Mayo Clinic in Rochester, Minnesota, on a study of early transplant in alcoholic liver disease.
“Medicare may be paying for opioids that are doing harm.” — Ann Maxwell of the Office of Inspector General, at a panel discussion on strategies to identify addiction issues in seniors.
“Health related quality of life is increasingly becoming a critical secondary endpoint in randomized clinical trials.” — Jonathan Strosberg, MD, of Moffitt Cancer Center in Tampa, Florida on the treatment of midgut neuroendocrine tumors.
“Physicians may want to consider discussing these findings with underweight premenopausal female patients.” — Kathleen Szegda, PhD, of the University of Massachusetts in Amherst, on risk factors for early menopause.
“When clinical features are equivocal in nature, molecular correlates such as the 92-gene assay [CancerTYPE ID] can address the unmet need to provide a more definitive diagnosis to select optimal treatments.” — Catherine Schnabel, PhD, of bioTheranostics in San Diego, on classifying neuroendocrine tumors.